Cerianna is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER) positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.

A tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status.  This imaging agent is not utilized to image other imaging receptors.

Women in the U.S. have a 1 in 8 lifetime risk of being diagnosed with breast cancer (source: breastcancer.org)